Clinically driven design of multi-scale cancer models: the ContraCancrum project paradigm

@article{Marias2011ClinicallyDD,
  title={Clinically driven design of multi-scale cancer models: the ContraCancrum project paradigm},
  author={Kostas Marias and Dimitra D. Dionysiou and Vangelis Sakkalis and Norbert M. Graf and Rainer Bohle and Peter V. Coveney and Shunzhou Wan and Amos A. Folarin and Philippe B{\"u}chler and Mauricio Reyes and Gordon Clapworthy and Enjie Liu and J{\"o}rg Sabczynski and Tom{\'a}{\vs} B{\'i}l{\'y} and Alexandros Roniotis and Manolis Tsiknakis and Eleni A. Kolokotroni and Stavroula G. Giatili and Christian Veith and E. Messe and Holger Stenzhorn and Yoo-Jin Kim and Stefan J. Zasada and Ali Nasrat Haidar and Christoph May and Stefan Bauer and T. Wang and Y. Zhao and Michal Kar{\'a}sek and R{\"u}diger Grewer and Astrid Franz and Georgios S. Stamatakos},
  journal={Interface Focus},
  year={2011},
  volume={1},
  pages={450 - 461}
}
The challenge of modelling cancer presents a major opportunity to improve our ability to reduce mortality from malignant neoplasms, improve treatments and meet the demands associated with the individualization of care needs. This is the central motivation behind the ContraCancrum project. By developing integrated multi-scale cancer models, ContraCancrum is expected to contribute to the advancement of in silico oncology through the optimization of cancer treatment in the patient-individualized… 

Figures from this paper

Navigating Multi-Scale Cancer Systems Biology Towards Model-Driven Clinical Oncology and Its Applications in Personalized Therapeutics

TLDR
It is concluded that the absence of a generic, zero-code, panomics-based multi-scale modeling pipeline and associated software framework, impedes the development and seamless deployment of personalized in silico multi- scale models in clinical settings.

Navigating Multi-scale Cancer Systems Biology towards Model-driven Personalized Therapeutics

TLDR
The review concludes by highlighting that the absence of a generic, zero-code, panomics-based multi-scale modeling pipeline and associated software framework, impedes the development and seamless deployment of personalized in silico multi- scale models in clinical settings.

Clinical implications of in silico mathematical modeling for glioblastoma: a critical review

TLDR
How close these models have come in predicting the outcome of treatment protocols and in shaping the future of radiotherapy treatments are examined, with focus on 3D modeling approaches of radiation response of in vivo glioblastomas based on contemporary imaging techniques.

Patient‐Specific Modelling in Drug Design, Development and Selection Including its Role in Clinical Decision‐Making

TLDR
It is shown here using case studies in cancer and HIV how such computational models, and particularly models based on individual patient data, can be used for drug design and development, and in the selection of the appropriate treatment for a given patient in the face of resistance mutations.

Integrated PK-PD and agent-based modeling in oncology

TLDR
This review focuses on some of the most recent modeling studies building on a combined PK-PD and ABM approach that have generated experimentally testable hypotheses.

In Silico Oncology: Quantificationof the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale MechanisticModel

TLDR
A mechanistic model of cancer response to treatment is applied for the estimation of a plausible value range of the cell killing efficacy of various cisplatin-based doublet regimens and provides a quantitative framework for the in-vivo cell-killing ability of various chemotherapies.

A study on the predictability of acute lymphoblastic leukaemia response to treatment using a hybrid oncosimulator

TLDR
A hybrid combination of computational optimization and machine learning methods with an already developed mechanistic model called the acute lymphoblastic leukaemia (ALL) Oncosimulator which simulates ALL progression and treatment response is presented and results obtained are particularly encouraging regarding the soundness of the proposed methodologies.

In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model

TLDR
A mechanistic model of cancer response to treatment is applied for the estimation of a plausible value range of the cell killing efficacy of various cisplatin-based doublet regimens and provides a quantitative framework for the in-vivo cell-killing ability of various chemotherapies.

E-Science technologies in a workflow for personalized medicine using cancer screening as a case study

TLDR
An e-Science perspective on the workflow from risk factor discovery and classification of disease to evaluation of personalized intervention programs, and generic concepts of the suggested eCPC workflow are transferrable to other disease domains, although each disease will require tailored solutions.

References

SHOWING 1-10 OF 45 REFERENCES

Exploiting Clinical Trial Data Drastically Narrows the Window of Possible Solutions to the Problem of Clinical Adaptation of a Multiscale Cancer Model

TLDR
The behavior of a clinically-oriented, multiscale model of solid tumor response to chemotherapy is investigated, using the paradigm of nephroblastoma response to preoperative chemotherapy in the context of the SIOP/GPOH clinical trial.

'In silico' oncology for clinical decision making in the context of nephroblastoma.

TLDR
The present paper outlines the initial version of the ACGT (Advancing Clinico-Genomic Trials)I-Oncosimulator as an integrated software system simulating in vivo tumour response to therapeutic modalities within the clinical trials environment aiming to support clinical decision making in individual patients.

Evaluation framework for the multilevel macroscopic models of solid tumor growth in the glioma case

TLDR
The promising results presented encourage the potential clinical applicability of the proposed model in the glioma case and identify crucial points and direction of further model refinement and research.

Contra Cancrum: Segmentation of Different Tissue Types in Lung Tumors from PET/CT Follow-Up Scans

TLDR
The methods used for registering morphological (CT) with functional (PET) images of the tumor as well as registering a time series of multimodal images before, during, and after therapy are described.

Introduction of Hypermatrix and Operator Notation into a Discrete Mathematics Simulation Model of Malignant Tumour Response to Therapeutic Schemes In Vivo. Some Operator Properties

TLDR
The introduction of the notion of hypermatrix in conjunction with that of a discrete operator into the already developed models of in vivo tumour growth and in particular tumour response to several therapeutic schemes is proposed.

The EuroPhysiome, STEP and a roadmap for the virtual physiological human

  • J. FennerB. Brook M. Viceconti
  • Medicine
    Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences
  • 2008
TLDR
This paper considers issues pertinent to the development of the VPH, highlighted by the work of the STEP consortium, to create a framework capable of describing Homo sapiens in silico.